Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Effect of adding immunotherapy to standard of care on survival in patients with esophageal cancer: Analysis of NCDB database.
Authors
SABER Ali AMIN
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
SABER Ali AMIN , Chi Lin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Therapeutics
DOI
10.1200/JCO.2022.40.4_suppl.325
Abstract #
325
Poster Bd #
L8
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical outcomes in phase 1 clinical trials (Ph1-CT) when treating patients (pts) with novel immunotherapy (IT) agents at early lines for advanced disease.
First Author: Juan José Soto
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Mathias Earl Palmer
Poster
2022 ASCO Annual Meeting
Outcomes of patients (pts) treated with novel immunotherapy (IT) agents in phase 1 clinical trials (Ph1-CT) at early lines for advanced disease.
First Author: Juan José Soto
Poster
2016 Gastrointestinal Cancers Symposium
Changes in treatment patterns for patients with locally advanced rectal cancer in the United States over the past decade: An analysis from the National Cancer Data Base (NCDB).
First Author: Helmneh M. Sineshaw